Walther will provide a one-for-one match for donors who establish endowed children’s cancer research funds at Riley Children’s Foundation, a move that could result in at least $20 million for research of new treatments of children’s cancers.
Read More
Retired since 2015, Bob Kevoian made a rare appearance Wednesday on the syndicated “Bob & Tom” show to publicly reveal his diagnosis.
Read More
The Indianapolis-based radiopharmaceutical company said it plans to help open a facility in Belgium to make therapeutic agents for cancer patients.
Read More
Illuccix was first approved by the FDA in December 2021. The imaging agent is designed to target and “light up” cancerous cells, making it easier for oncologists to determine through a PET scan if the cells have spread to areas outside the prostate.
Read More
The test, one of the first of its kind, is designed to reach patients who may forgo traditional screening because of lack of access, past trauma or embarrassment.
The Carmel center, which opened Monday, has 17 infusion rooms, eight rooms for clinical visits, a procedure room and a pharmacy.
Bayer, which acquired Monsanto in 2018, has continued to dispute claims that Roundup causes cancer. But the company has been hit with more than 177,000 lawsuits involving the weedkiller and set aside $16 billion to settle cases.
Indianapolis has been awash in Big Ten logos amid the conference’s basketball tournaments. But Indy is home to another sort of Big Ten gathering—one focused on improving cancer research.
The Indianapolis-based drugmaker will acquire Scorpion’s STX-478, a once-daily oral treatment in early trials for breast cancer and other advanced solid tumors.
The Indianapolis-based hospital system wants to add 34,645 square feet to its MD Anderson Cancer Center at 7979 Shadeland Ave., on the Community Hospital North campus.
The test isn’t a replacement for colonoscopies, but provides a noninvasive approach to screening.
The study followed a group of testicular cancer survivors for an average of 14 years, revealing that 78% experience significant difficulties in everyday listening situations.
At issue is whether a drug developed by Point Biopharma, based in Indianapolis, infringed on a patent issued in 2020 and assigned to Purdue Research Foundation.
Novartis Manufacturing LLC told a committee of the City-County Council on Monday evening that it plans to spend up to $125 million to construct and equip a 79,000-square-foot-building for radiopharmaceutical manufacturing and distribution on the city’s west side.
Following a $45 million renovation, RayzeBio plans to use the plant to make Actinium 225, a radioisotope used for targeted therapy for cancer.
Mandy Pietrykowski succeeds Fred Duncan, who retired this week after leading the Indianapolis-based agency since 2009.
The Indianapolis-based pharmaceutical company is preparing for one of its most ambitious years in memory for 2023, with plans to advance five new drugs into late-stage clinical studies and move four into regulatory review.
A 10-year study by researchers from Poland, Norway and Sweden published in the New England Journal of Medicine questions the benefits of colonoscopy screening exams.
Point Biopharma is moving aggressively to get its lead drug, a radioactive isotope called lutetium 177, through late-stage trials for prostate cancer.
Three Indiana institutions are teaming up to try to develop a treatment for glioblastoma, a lethal cancer that begins with the brain or spinal cord, and is difficult to treat, often requiring a combination of surgery, chemotherapy and radiation.
The imaging agent is the six-year-old company’s first commercial launch, following millions of dollars’ worth of research and clinical tests. It was approved by the U.S. Food and Drug Administration in December.
The medical school said the commitment will help launch research efforts to develop better therapies for triple negative breast cancer, an aggressive form of breast cancer that is often not responsive to hormone therapies and is resistant to chemotherapy.
Brooke Beier, senior vice president of commercialization at the Purdue Research Foundation, said FDA approval of the therapy is one of the most meaningful approvals ever for a Purdue-related innovation.
It’s a big moment for On Target Laboratories, an 11-year-old biotech based in West Lafayette. The FDA approval marks the company’s first novel compound to get across the finish line. The drug is marketed under the brand name Cytalux.
